Review Article
Future Therapies of Wet Age-Related Macular Degeneration
Table 1
Summary of neovascular AMD therapeutic agents, mechanisms, route, and phase of development.
| Agent | Mechanism | Treatment | Phase |
| E10030 | Platelet-derived growth factor (PDGF) inhibitor | iv | 3 |
| Sirolimus | Mammalian target of rapamycin (mTOR) inhibitor | iv sc | 2 |
| Infliximab | Anti-tumor necrosis factor alpha (TNF-) antibody | iv | 1 |
| POT-4 | Complement component 3 (C3) inhibitor | iv | 2 |
| JSM6427 | Integrin receptor antagonist | iv | 1 |
| Volociximab | Anti-v1 integrin monocle antibody | iv | 1 |
| ALG-1001 | Integrin receptor antagonist | iv | 2a |
| ATG003 | Nicotinic acetylcholine receptor (nAchR) antagonist | Eye drop | 2 |
| AdPEDF.11 | Transgene for cDNA of human PEDF | iv | 1 |
| Methotrexate | Antifolate drug | iv | ā |
| Triple combination therapy (verteporfin-ranibizumab-dexamethasone) | Targeting multiple components of choroidal neovascularization | iv (ranibizumab, dexamethasone) after VPDT | 2 |
|
|
iv: intravitreal injection; sc: subconjunctival injection. VPDT: verteporfin photodynamic therapy.
|